Cited by 696Cancer survivorship and careCancer-related cognitive impairment studiesHealth Systems, Economic Evaluations, Quality of Life

The DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.

Measuring quality of life in men with prostate cancer using the Functional Assessment of Cancer Therapy-prostate instrument

Esper, Peg, Mo, Fei, Chodak, Gerald, Sinner, Michael, Cella, David, Pienta, Kenneth J.·1997·Urology

DOI 10.1016/s0090-4295(97)00459-7

Open this paper in CoChat — free account

Abstract

Objectives As the incidence of prostate cancer in the United States exceeds 330,000 in 1997, increasingly more men are faced with treatment choices for which there is no clear approach. At every stage of disease, these treatment choices may involve clinically equivalent modalities that differ in side effects and impact upon quality of life (QOL). Comprehensive, yet efficient, questionnaires are needed to measure QOL in patients with prostate cancer.Methods Developed as a disease-specific adjunct to the Functional Assessment of Cancer Therapy (FACT) measurement system, a 12-item prostate cancer subscale (PCS) was developed and tested in three independent samples: a subscale development sample (n = 43), validity sample 1 (n = 34), and validity sample 2 (n = 96). The 12 items ask about symptoms and problems specific to prostate cancer. These questions are added to the general (FACT-G) instrument, thereby comprising a 47-item questionnaire.Results Internal consistency of the PCS ranged from 0.65 to 0.69, with coefficients for FACT-G subscales and aggregated scores ranging from 0.61 to 0.90. Concurrent validity was confirmed by the ability to discriminate patients by disease stage, performance status, and baseline prostate-specific antigen (PSA) level. Sensitivity to change in performance status and PSA score over a 2-month period suggested that some subscales of the FACT-Prostate (P) (including the PCS) are sensitive to meaningful clinical change.Conclusions Our findings support use of the FACT-P as a meaningful component of QOL evaluation in men undergoing therapy for prostate cancer.

Integrity signals

Registry

Crossref · 10.1016/s0090-4295(97)00459-7

Cites

22 of 22 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

The functional assessment of cancer therapy scale: development and validation of the general measure
Cella, D. F., Tulsky, D. S., Gray, G., Sarafian, B., Linn, E., Bonomi, A., Silberman, M., Yellen, S. B., Winicour, P., & Brannon, J. (1993) · Journal of Clinical Oncology · doi:10.1200/jco.1993.11.3.570 · Cited by 6,020
Self-citation
Cancer statistics, 1997
Parker, S. L., Tong, T., Bolden, S., & Wingo, P. A. (1997) · CA A Cancer Journal for Clinicians · doi:10.3322/canjclin.47.1.5 · Cited by 2,000
Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points.
Tannock, I. F., Osoba, D., Stockler, M. R., Ernst, D. S., Neville, A. J., Moore, M. J., Armitage, G. R., Wilson, J. J., Venner, P. M., Coppin, C., et al. (1996) · Journal of Clinical Oncology · doi:10.1200/jco.1996.14.6.1756 · Cited by 1,575
Quality-of-life outcomes in men treated for localized prostate cancer
Litwin, M. S., Hays, R. D., Fink, A., Ganz, P. A., Leake, B., Leach, G. E., & Brook, R. H. (1995) · JAMA · doi:10.1001/jama.1995.03520260051032 · Cited by 1,020
Reliability and validity of the functional assessment of cancer therapy—lung (FACT-L) quality of life instrument
Cella, D. F., Bonomi, A. E., Lloyd, S. R., Tulsky, D. S., Kaplan, E. J., & Bonomi, P. (1995) · Lung Cancer · doi:10.1016/0169-5002(95)00450-f · Cited by 750
Self-citation
Treatment of metastatic prostatic cancer with low-dose prednisone: evaluation of pain and quality of life as pragmatic indices of response.
Tannock, I. F., Gospodarowicz, M., Meakin, W., Panzarella, T., Stewart, L., & Rider, W. D. (1989) · Journal of Clinical Oncology · doi:10.1200/jco.1989.7.5.590 · Cited by 407
Quality-of-life outcomes in men treated for localized prostate cancer
Litwin, M. S. (1995) · JAMA · doi:10.1001/jama.273.2.129 · Cited by 281
The association of benign prostatic hyperplasia and cancer of the prostate
Bostwick, D. G., Cooner, W. H., Denis, L., Jones, G. W., Scardino, P. T., & Murphy, G. P. (1992) · Cancer · doi:10.1002/1097-0142(19920701)70:1+ · Cited by 222
Early Detection of Prostate Cancer
Scardino, P. T. (1989) · Urologic Clinics of North America · doi:10.1016/s0094-0143(21)01800-0 · Cited by 210
Quality of Life and Functional Status Measures in Patients With Head and Neck Cancer
DʼAntonio, L. L., Zimmerman, G. J., Cella, D. F., & Long, S. A. (1996) · Archives of Otolaryngology - Head and Neck Surgery · doi:10.1001/archotol.1996.01890170018005 · Cited by 197
Self-citation

Show all 22 references

Research works printed but not linked: 2

da Silva, 1993, Quality of life in patients with prostatic cancer. A feasibility study, Cancer, 71, 1138, 10.1002/1097-0142(19930201)71:3+<1138::AID-CNCR2820711436>3.0.CO;2-7 · DOI
Esper, 1995, FACT-P: a new instrument for quality of life evaluation in prostate cancer (abstract), J Urol, 153

Sorted by citations

Docetaxel plus Prednisone or Mitoxantrone plus Prednisone for Advanced Prostate Cancer
Tannock, I. F., de Wit, R., Berry, W. R., Horti, J., Pluzanska, A., Chi, K. N., Oudard, S., Théodore, C., James, N. D., Turesson, I., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040720 · Cited by 5,735
Abiraterone and Increased Survival in Metastatic Prostate Cancer
de Bono, J. S., Logothetis, C. J., Molina, A., Fizazi, K., North, S., Chu, L., Chi, K. N., Jones, R. J., Goodman, O. B., Saad, F., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1014618 · Cited by 4,407
“Arthralgia 215 (27) 33 (4) 0 89 (23) 16 (4) 0”
Increased Survival with Enzalutamide in Prostate Cancer after Chemotherapy
Scher, H. I., Fizazi, K., Saad, F., Taplin, M.-E., Sternberg, C. N., Miller, K., de Wit, R., Mulders, P., Chi, K. N., Shore, N. D., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1207506 · Cited by 4,586
Apalutamide for Metastatic, Castration-Sensitive Prostate Cancer
Chi, K. N., Agarwal, N., Bjartell, A., Chung, B. H., Pereira de Santana Gomes, A. J., Given, R., Juárez Soto, Á., Merseburger, A. S., Özgüroğlu, M., Uemura, H., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1903307 · Cited by 1,564
Development and validation of the expanded prostate cancer index composite (EPIC) for comprehensive assessment of health-related quality of life in men with prostate cancer
Wei, J. T., Dunn, R. L., Litwin, M. S., Sandler, H. M., & Sanda, M. G. (2000) · Urology · doi:10.1016/s0090-4295(00)00858-x · Cited by 1,520
The Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System: properties, applications, and interpretation.
(2003) · Health and Quality of Life Outcomes · doi:10.1186/1477-7525-1-79 · Cited by 1,506
Self-citation
Docetaxel Plus Prednisone or Mitoxantrone Plus Prednisone for Advanced Prostate Cancer: Updated Survival in the TAX 327 Study
Berthold, D. R., Pond, G. R., Soban, F., de Wit, R., Eisenberger, M., & Tannock, I. F. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.12.4008 · Cited by 1,145
Escalated-dose versus standard-dose conformal radiotherapy in prostate cancer: first results from the MRC RT01 randomised controlled trial
Dearnaley, D. P., Sydes, M. R., Graham, J. D., Aird, E. G. A., Bottomley, D., Cowan, R. A., Huddart, R. A., Jose, C. C., Matthews, J. H. L., Millar, J. L., et al. (2007) · The Lancet Oncology · doi:10.1016/s1470-2045(07)70143-2 · Cited by 906
The UCLA Prostate Cancer Index
Litwin, M. S., Hays, R. D., Fink, A., Ganz, P. A., LEAKE, B. D., & Brook, R. H. (1998) · Medical Care · doi:10.1097/00005650-199807000-00007 · Cited by 819
Combined androgen deprivation therapy and radiation therapy for locally advanced prostate cancer: a randomised, phase 3 trial
Warde, P. R., Mason, M., Ding, K., Kirkbride, P., Brundage, M., Cowan, R. A., Gospodarowicz, M. K., Sanders, K., Kostashuk, E. C., Swanson, G. P., et al. (2011) · The Lancet · doi:10.1016/s0140-6736(11)61095-7 · Cited by 579
Meaningful change in cancer-specific quality of life scores: Differences between improvement and worsening
Cella, D. F., Hahn, E. A., & Dineen, K. K. (2002) · Quality of Life Research · doi:10.1023/a:1015276414526 · Cited by 523
“When comparing these results to the findings of previous studies using the FACT questionnaire, including mixed cancer [25], breast cancer [24], lung cancer [23], head and neck cancer [28, 44], and prostate cancer [ 27 ], we find in general that changes of 2–3 raw scale points in the PWB and FWB subscales are associate…”
ResultSelf-citation
An international field study of the EORTC QLQ-PR25: A questionnaire for assessing the health-related quality of life of patients with prostate cancer
van Andel, G., Bottomley, A., Fosså, S. D., Efficace, F., Coens, C., Guerif, S. G., Kynaston, H., Gontero, P., Thalmann, G. N., Akdaş, A., et al. (2008) · European Journal of Cancer · doi:10.1016/j.ejca.2008.07.030 · Cited by 494
Reliability and validity of the Functional Assessment of Cancer Therapy-Colorectal (FACT-C) quality of life instrument
Ward, W. L., Hahn, E. A., Mo, F., Hernández, L., Tulsky, D. S., & Cella, D. F. (1999) · Quality of Life Research · doi:10.1023/a:1008821826499 · Cited by 470
Self-citation
Global Trends and Prostate Cancer: A Review of Incidence, Detection, and Mortality as Influenced by Race, Ethnicity, and Geographic Location
Taitt, H. E. (2018) · American Journal of Men s Health · doi:10.1177/1557988318798279 · Cited by 463
“This contrasts with the United States, where only about 15% of patients were diagnosed at an advanced stage at initial presentation during the same period (Esper et al., 1997).”
Result
Development and Validation of an Abbreviated Version of the Expanded Prostate Cancer Index Composite Instrument for Measuring Health-related Quality of Life Among Prostate Cancer Survivors
Szymanski, K. M., Wei, J. T., Dunn, R. L., & Sanda, M. G. (2010) · Urology · doi:10.1016/j.urology.2010.01.027 · Cited by 457
Comprehensive Comparison of Health-Related Quality of Life After Contemporary Therapies for Localized Prostate Cancer
Wei, J. T., Dunn, R. L., Sandler, H. M., McLaughlin, P. W., Montie, J. E., Litwin, M. S., NYQUIST, L. V., & Sanda, M. G. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.20.2.557 · Cited by 443
Focal therapy for localised unifocal and multifocal prostate cancer: a prospective development study
Ahmed, H. U., Hindley, R. G., Dickinson, L., Freeman, A., Kirkham, A. P. S., Sahu, M., Scott, R., ALLEN, C. M., van der Meulen, J., & Emberton, M. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(12)70121-3 · Cited by 397
Effect of Endothelin-A Receptor Blockade With Atrasentan on Tumor Progression in Men With Hormone-Refractory Prostate Cancer: A Randomized, Phase II, Placebo-Controlled Trial
Carducci, M. A., Padley, R. J., Breul, J., Vogelzang, N. J., Zonnenberg, B. A., Daliani, D., Schulman, C. C., Nabulsi, A. A., Humerickhouse, R. A., Weinberg, M. A., et al. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.04.176 · Cited by 370
The significance of skeletal-related events for the health-related quality of life of patients with metastatic prostate cancer
Weinfurt, K. P., Li, Y., Castel, L. D., Fred Saad, C., Timbie, J. W., Glendenning, G. A., & Schulman, K. A. (2005) · Annals of Oncology · doi:10.1093/annonc/mdi122 · Cited by 362
“FACT-G scores were comparable to those reported in other studies of prostate cancer [7, 10 ].”
BackgroundResult
177Lu-PSMA-617 versus a change of androgen receptor pathway inhibitor therapy for taxane-naive patients with progressive metastatic castration-resistant prostate cancer (PSMAfore): a phase 3, randomised, controlled trial
Morris, M. J., Castellano, D., Herrmann, K., de Bono, J. S., Shore, N. D., Chi, K. N., Crosby, M., Piulats, J. M., Fléchon, A., Wei, X. X., et al. (2024) · The Lancet · doi:10.1016/s0140-6736(24)01653-2 · Cited by 362
Recommended Patient-Reported Core Set of Symptoms to Measure in Adult Cancer Treatment Trials
Reeve, B. B., Mitchell, S. A., Dueck, A. C., Basch, E., Cella, D. F., Reilly, C. M., Minasian, L. M., Denicoff, A. M., O’Mara, A. M., Fisch, M. J., et al. (2014) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/dju129 · Cited by 359
Self-citation
Aflibercept versus placebo in combination with docetaxel and prednisone for treatment of men with metastatic castration-resistant prostate cancer (VENICE): a phase 3, double-blind randomised trial
Tannock, I. F., Fizazi, K. S., Иванов, С. А., Karlsson, C. T., Fléchon, A., Skoneczna, I. A., Orlandi, F. J., Gravis, G., Matveev, V., Bavbek, S. E., et al. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70184-0 · Cited by 288
Main Outcomes of the FRESH START Trial: A Sequentially Tailored, Diet and Exercise Mailed Print Intervention Among Breast and Prostate Cancer Survivors
Demark‐Wahnefried, W., Clipp, E. C., Lipkus, I. M., Lobach, D. F., Snyder, D. C., Sloane, R. J., Peterson, B. L., Macri, J. M., Rock, C. L., McBride, C. M., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.10.7094 · Cited by 290
Reliability and validity of the functional assessment of cancer therapy-ovarian
Basen-Engquist, K., Bodurka-Bevers, D., Fitzgerald, M. A., Webster, K., Cella, D., Hu, S., & Gershenson, D. M. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.6.1809 · Cited by 280
Self-citation
Measuring quality of life in chronic illness: The functional assessment of chronic illness therapy measurement system
Cella, D. F., & Nowinski, C. J. (2002) · Archives of Physical Medicine and Rehabilitation · doi:10.1053/apmr.2002.36959 · Cited by 279
Self-citation
Exercise Interventions for Cancer Survivors: A Meta-Analysis of Quality of Life Outcomes
Ferrer, R. A., Huedo-Medina, T. B., Johnson, B. T., Ryan, S. M., & Pescatello, L. S. (2010) · Annals of Behavioral Medicine · doi:10.1007/s12160-010-9225-1 · Cited by 282
Fear of cancer recurrence: a systematic literature review of self‐report measures
Thewes, B., Butow, P., Zachariae, R., Christensen, S., Simard, S., & Gotay, C. (2012) · Psycho-Oncology · doi:10.1002/pon.2070 · Cited by 262
Evaluation of quality of life after laparoscopic surgery: evidence-based guidelines of the European Association for Endoscopic Surgery
Korolija, D., Sauerland, S., Wood-Dauphinée, S., Abbou, C. C., Eypasch, E. P., Caballero, M. G., Lumsden, M. A., Millat, B., Monson, J. R. T., Nilsson, G., et al. (2004) · Surgical Endoscopy · doi:10.1007/s00464-003-9263-x · Cited by 250
Lifestyle Intervention Development Study to Improve Physical Function in Older Adults With Cancer: Outcomes From Project LEAD
Demark‐Wahnefried, W., Clipp, E. C., Morey, M. C., Pieper, C. F., Sloane, R. J., Snyder, D. C., & Cohen, H. J. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.05.7224 · Cited by 243
Focal Therapy for Localized Prostate Cancer: A Phase I/II Trial
Ahmed, H. U., Freeman, A., Kirkham, A. P. S., Sahu, M., Scott, R., ALLEN, C. M., van der Meulen, J., & Emberton, M. (2011) · The Journal of Urology · doi:10.1016/j.juro.2010.11.079 · Cited by 233
The Memorial Anxiety Scale for Prostate Cancer: Validation of a new scale to measure anxiety in men with prostate cancer
Roth, A. J., Rosenfeld, B., Kornblith, A. B., Gibson, C., Scher, H. I., Curley‐Smart, T., Holland, J. C., & Breitbart, W. (2003) · Cancer · doi:10.1002/cncr.11386 · Cited by 229
Preliminary experience with dosimetry, response and patient reported outcome after 177Lu-PSMA-617 therapy for metastatic castration-resistant prostate cancer
Fendler, W. P., Reinhardt, S., Ilhan, H., Delker, A., Böning, G., Gildehaus, F. J., Stief, C. G., Bartenstein, P., Gratzke, C., Lehner, S., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.12240 · Cited by 228
Developing a Valid Patient-Reported Outcome Measure
Rothrock, N. E., Kaiser, K. A., & Cella, D. (2011) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2011.195 · Cited by 222
Self-citation
Living With Prostate Cancer: Patients' and Spouses' Psychosocial Status and Quality of Life
Northouse, L., Mood, D., Montie, J. E., Sandler, H. M., Forman, J. D., Hussain, M., Pienta, K. J., Smith, D. C., Sanda, M. G., & Kershaw, T. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.09.6503 · Cited by 213
Self-citation
Estimating Clinically Meaningful Changes for the Functional Assessment of Cancer Therapy—Prostate: Results from a Clinical Trial of Patients with Metastatic Hormone-Refractory Prostate Cancer
Cella, D. F., Nichol, M. B., Eton, D. T., Nelson, J. B., & Mulani, P. M. (2008) · Value in Health · doi:10.1111/j.1524-4733.2008.00409.x · Cited by 213
Self-citation
2-weekly versus 3-weekly docetaxel to treat castration-resistant advanced prostate cancer: a randomised, phase 3 trial
Kellokumpu‐Lehtinen, P., Harmenberg, U., Joensuu, T. K., McDermott, R., Hervonen, P., Ginman, C., Luukkaa, M., Nyandoto, P., Hemminki, A., Nilsson, S. F., et al. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(12)70537-5 · Cited by 214
Randomized Phase II Study of Two Doses of Gefitinib in Hormone-Refractory Prostate Cancer: A Trial of the National Cancer Institute of Canada-Clinical Trials Group
Canil, C. M., Moore, M. J., Winquist, E., Baetz, T. D., Pollak, M., Chi, K. N., Berry, S. R., Ernst, D. S., Douglas, L., Brundage, M., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.02.129 · Cited by 209
“If capable, patients must have been willing to complete quality-of-life assessments (Functional Assessment of Cancer Therapy Prostate Cancer Subscale [FACT-P]) in either English or French.30 Requirements for organ function were absolute granulocytes 1.5 109/L, platelets 100 109/L, serum creatinine and 456 JOURNAL OF C…”
BackgroundInfluential
Treatment of Hormone-Refractory Prostate Cancer with Docetaxel or Mitoxantrone: Relationships between Prostate-Specific Antigen, Pain, and Quality of Life Response and Survival in the TAX-327 Study
Berthold, D., Pond, G. R., Roessner, M., de Wit, R., Eisenberger, M. A., Tannock, A. I. F., & on behalf of the TAX-327 investigators (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-0944 · Cited by 207
Lifestyle Changes for Improving Disease-specific Quality of Life in Sedentary Men on Long-term Androgen-Deprivation Therapy for Advanced Prostate Cancer: A Randomised Controlled Trial
Bourke, L., Gilbert, S. E., Hooper, R., Steed, L., Joshi, M., Catto, J. W. F., Saxton, J., & Rosario, D. J. (2013) · European Urology · doi:10.1016/j.eururo.2013.09.040 · Cited by 205
“Disease-specific QoL was assessed by the FACT-P questionnaire [22], patient-reported fatigue was assessed using the FACT-Fatigue questionnaire [23], total exercise behaviour by the Godin Leisure Score Index [24], and aerobic exercise”
Method
Focal Ablation Targeted to the Index Lesion in Multifocal Localised Prostate Cancer: a Prospective Development Study
Ahmed, H. U., Dickinson, L., Charman, S. C., Weir, S., McCartan, N., Hindley, R. G., Freeman, A., Kirkham, A. P. S., Sahu, M., Scott, R., et al. (2015) · European Urology · doi:10.1016/j.eururo.2015.01.030 · Cited by 201
Management of Complications of Prostate Cancer Treatment
Michaelson, M. D., Cotter, S. E., Gargollo, P. C., Zietman, A. L., Dahl, D. M., & Smith, M. R. (2008) · CA: A Cancer Journal for Clinicians · doi:10.3322/ca.2008.0002 · Cited by 196
Effect of enzalutamide on health-related quality of life, pain, and skeletal-related events in asymptomatic and minimally symptomatic, chemotherapy-naive patients with metastatic castration-resistant prostate cancer (PREVAIL): results from a randomised, phase 3 trial
Loriot, Y., Miller, K., Sternberg, C. N., Fizazi, K. S., Bono, J. S. D., Chowdhury, S., Higano, C. S., Noonberg, S. B., Holmström, S., Mansbach, H. H., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)70113-0 · Cited by 192
Patient-reported quality-of-life analysis of radium-223 dichloride from the phase III ALSYMPCA study
Nilsson, S. F., Cislo, P. R., Sartor, O. A., Vogelzang, N. J., Coleman, R. E., O’Sullivan, J. M., Reuning-Scherer, J. D., Shan, M., Zhan, L., & Parker, C. C. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw065 · Cited by 184
“The ALSYMPCA design included prospective QOL measurements using two validated instruments: EuroQoL EQ-5D, designed for the general population, and Functional Assessment of Cancer TherapyProstate (FACT-P), a disease-specific questionnaire for patients with prostate cancer [15, 16].”
Method
Transrectal high-intensity focused ultrasound for treatment of patients with stage T1b-2n0m0 localized prostate cancer: a preliminary report
Uchida, Τ., Sanghvi, N. T., Gardner, T. A., Koch, M. O., Ishii, D., Minei, S., Satoh, T., Hyodo, T., Irie, A., & Baba, S. (2002) · Urology · doi:10.1016/s0090-4295(01)01624-7 · Cited by 183
Health-Related Quality of Life 2 Years After Treatment With Radical Prostatectomy, Prostate Brachytherapy, or External Beam Radiotherapy in Patients With Clinically Localized Prostate Cancer
Ferrer, M., Suárez, J. F., Guedea, F., Fernández, P., Macías, V., Mariño, A., Hervas, A., Herruzo, I., Ortiz, M. J., Villavicencio, H., et al. (2008) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2007.12.024 · Cited by 181
“(35, 36) and contains 12 questions about urinary symptoms and bowel”
Background
Exercise Prevents Fatigue and Improves Quality of Life in Prostate Cancer Patients Undergoing Radiotherapy
Monga, U., Garber, S. L., Thornby, J. A., Vallbona, C., Kerrigan, A. J., Monga, T. N., & Zimmermann, K. P. (2007) · Archives of Physical Medicine and Rehabilitation · doi:10.1016/j.apmr.2007.08.110 · Cited by 179
Health Related Quality of Life in Men With Prostate Cancer
Penson, D. F., Litwin, M. S., & Aaronson, N. K. (2003) · The Journal of Urology · doi:10.1097/01.ju.0000061964.49961.55 · Cited by 176
Patient-reported outcomes following abiraterone acetate plus prednisone added to androgen deprivation therapy in patients with newly diagnosed metastatic castration-naive prostate cancer (LATITUDE): an international, randomised phase 3 trial
Chi, K. N., Protheroe, A. S., Rodríguez-Antolín, A., Facchini, G., Suttmann, H., Matsubara, N., Ye, Z., Keam, B., Damião, R., Li, T. M. W. Y., et al. (2018) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30911-7 · Cited by 171
Lifestyle Intervention in Men with Advanced Prostate Cancer Receiving Androgen Suppression Therapy: A Feasibility Study
Bourke, L., Doll, H., Crank, H., Daley, A., Rosario, D. J., & Saxton, J. (2011) · Cancer Epidemiology Biomarkers & Prevention · doi:10.1158/1055-9965.epi-10-1143 · Cited by 168
Phase II Trial of Oral Estramustine, Oral Etoposide, and Intravenous Paclitaxel in Hormone-Refractory Prostate Cancer
Smith, D. C., Esper, P., Strawderman, M. S., Redman, B. G., & Pienta, K. J. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.6.1664 · Cited by 158
Self-citation
Hypofractionated radiotherapy versus conventionally fractionated radiotherapy for patients with intermediate-risk localised prostate cancer: 2-year patient-reported outcomes of the randomised, non-inferiority, phase 3 CHHiP trial
Wilkins, A. C., Mossop, H., Syndikus, I., Khoo, V. S., Bloomfield, D. J., Parker, C. C., Logue, J. P., Scrase, C. D., Patterson, H., Birtle, A. J., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00280-6 · Cited by 149
Quality of Life in Advanced Prostate Cancer: Results of a Randomized Therapeutic Trial
Moinpour, C. M., Lovato, L. C., Yee, M., Blumenstein, B. A., Savage, M. J., Troxel, A. B., Eisenberger, M. A., Veith, R. W., Higgins, B., Skeel, R. T., et al. (1998) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/90.20.1537 · Cited by 148
Effects of skeletal morbidities on longitudinal patient-reported outcomes and survival in patients with metastatic prostate cancer
DePuy, V., Anstrom, K. J., Castel, L. D., Schulman, K. A., Weinfurt, K. P., & Fred Saad, C. (2007) · Supportive Care in Cancer · doi:10.1007/s00520-006-0203-x · Cited by 145
“The FACT-G has acceptable psychometric reliability, validity, and sensitivity to change in populations with mixed cancer types [4, 6, 8, 17, 22, 25].”
Method
Follow-up modalities in focal therapy for prostate cancer: results from a Delphi consensus project
Muller, B. G., van den Bos, W., Brausi, M. A., Fütterer, J. J., Ghai, S., Pinto, P. A., Popeneciu, I. V., de Reijke, T. M., Robertson, C. N., de la Rosette, J. J. M. C. H., et al. (2015) · World Journal of Urology · doi:10.1007/s00345-014-1475-2 · Cited by 140
“The FACT-P questionnaire has been validated for assessment of QoL after radiotherapy for prostate cancer [24].”
Assessing Anxiety in Men With Prostate Cancer: Further Data on the Reliability and Validity of the Memorial Anxiety Scale for Prostate Cancer (MAX–PC)
Roth, A. J. L., Nelson, C. J., Rosenfeld, B. D., Warshowski, A., O'Shea, N., Scher, H. I., Holland, J. C., Slovin, S. F., Curley, T., Reynolds, T. R., et al. (2006) · Psychosomatics · doi:10.1176/appi.psy.47.4.340 · Cited by 139
Measuring Patientsʼ Perceptions of the Outcomes of Treatment for Early Prostate Cancer
Clark, J. A., Bokhour, B. G., Inui, T. S., Silliman, R. A., & Talcott, J. A. (2003) · Medical Care · doi:10.1097/00005650-200308000-00006 · Cited by 137
A prospective quality-of-life study in men with clinically localized prostate carcinoma treated with radical prostatectomy, external beam radiotherapy, or interstitial brachytherapy
Lee, W. R., Hall, M. C., McQuellon, R. P., Case, L. D., & McCullough, D. L. (2001) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/s0360-3016(01)01707-2 · Cited by 135
Health-Related Quality of Life, Psychological Distress, and Sexual Changes Following Prostate Cancer: A Comparison of Gay and Bisexual Men with Heterosexual Men
Ussher, J. M., Perz, J., Kellett, A., Chambers, S. K., Latini, D. M., Davis, I. D., Rose, D., Dowsett, G. W., & Williams, S. (2016) · The Journal of Sexual Medicine · doi:10.1016/j.jsxm.2015.12.026 · Cited by 133
Effect of apalutamide on health-related quality of life in patients with non-metastatic castration-resistant prostate cancer: an analysis of the SPARTAN randomised, placebo-controlled, phase 3 trial
Fred Saad, C., Cella, D. F., Basch, E., Hadaschik, B. A., Mainwaring, P. N., Oudard, S. M., Graff, J. N., McQuarrie, K., Li, S., Hudgens, S. A., et al. (2018) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30456-x · Cited by 131
Self-citation
RECOVERY OF HEALTH RELATED QUALITY OF LIFE IN THE YEAR AFTER RADICAL PROSTATECTOMY: EARLY EXPERIENCE
Litwin, M. S., McGuigan, K. A., Shpall, A. I., & Dhanani, N. (1999) · The Journal of Urology · doi:10.1016/s0022-5347(01)61938-4 · Cited by 130
How Does Active Surveillance for Prostate Cancer Affect Quality of Life? A Systematic Review
Bellardita, L., Valdagni, R., van den Bergh, R. C. N., Randsdorp, H., Repetto, C., Venderbos, L. D. F., Lane, J. A., & Korfage, I. J. (2014) · European Urology · doi:10.1016/j.eururo.2014.10.028 · Cited by 132
Health-related quality of life and pain outcomes with [177Lu]Lu-PSMA-617 plus standard of care versus standard of care in patients with metastatic castration-resistant prostate cancer (VISION): a multicentre, open-label, randomised, phase 3 trial
Fizazi, K., Herrmann, K., Krause, B. J., Rahbar, K., Chi, K. N., Morris, M. J., Sartor, O., Tagawa, S. T., Kendi, A. T., Vogelzang, N., et al. (2023) · The Lancet Oncology · doi:10.1016/s1470-2045(23)00158-4 · Cited by 125
The Association Between Erectile Dysfunction and Depressive Symptoms in Men Treated for Prostate Cancer
Nelson, C. J., Mulhall, J. P., & Roth, A. J. (2011) · The Journal of Sexual Medicine · doi:10.1111/j.1743-6109.2010.02127.x · Cited by 123
The Role of Spirituality in the Relationship Between Religiosity and Depression in Prostate Cancer Patients
Nelson, C., Jacobson, C. M., Weinberger, M. I., Bhaskaran, V., Rosenfeld, B., Breitbart, W., & Roth, A. J. (2009) · Annals of Behavioral Medicine · doi:10.1007/s12160-009-9139-y · Cited by 118
“The internal consistency of the FACT-P subscale is adequate, with an alpha coefficient of 0.69 [ 54 ].”
MethodInfluential
Health-related quality of life after apalutamide treatment in patients with metastatic castration-sensitive prostate cancer (TITAN): a randomised, placebo-controlled, phase 3 study
Agarwal, N., McQuarrie, K., Bjartell, A. S., Chowdhury, S., Gomes, A. J., Chung, B. H., Özgüroğlu, M., Soto, Á. J., Merseburger, A. S., Uemura, H., et al. (2019) · The Lancet Oncology · doi:10.1016/s1470-2045(19)30620-5 · Cited by 120
Self-citation
Carbon ion radiation therapy for prostate cancer: Results of a prospective phase II study
Ishikawa, H., Tsuji, H., Kamada, T., Yanagi, T., Mizoe, J., Kanai, T., Morita, S., Wakatsuki, M., Shimazaki, J., & Tsujii, H. (2006) · Radiotherapy and Oncology · doi:10.1016/j.radonc.2006.08.015 · Cited by 116
“To assess quality of life (QOL), measurement tools including the Functional Assessment of Cancer Therapy (FACT)-general (G) and the FACT-prostate (P) were administered before and immediately after and 1 year after C-ion RT [8].”
Method
Impact of resistance training on body composition and metabolic syndrome variables during androgen deprivation therapy for prostate cancer: a pilot randomized controlled trial
Dawson, J. K., Dorff, T. B., Todd Schroeder, E., Lane, C. J., Gross, M. E., & Dieli-Conwright, C. M. (2018) · BMC Cancer · doi:10.1186/s12885-018-4306-9 · Cited by 112
Reliability across studies from the functional assessment of cancer therapy-general (FACT-G) and its subscales: a reliability generalization
Victorson, D., Barocas, J., Song, J., & Cella, D. (2008) · Quality of Life Research · doi:10.1007/s11136-008-9398-2 · Cited by 141
Self-citation
Survival and PSA response of patients in the TAX 327 study who crossed over to receive docetaxel after mitoxantrone or vice versa
Berthold, D., Pond, G. R., de Wit, R., Eisenberger, M. A., & Tannock, I. F. (2008) · Annals of Oncology · doi:10.1093/annonc/mdn288 · Cited by 107
“Patients underwent physical exam as well as imaging and determination of serum PSA at baseline; they were required to complete a pain questionnaire and to document their analgesic consumption and QoL using the Functioned Assessment of Cancer Therapy-Prostate (FACT-P) questionnaire [10].”
Method
Patient-reported outcomes following enzalutamide or placebo in men with non-metastatic, castration-resistant prostate cancer (PROSPER): a multicentre, randomised, double-blind, phase 3 trial
TOMBAL, B. F., Fred Saad, C., Penson, D. F., Hussain, M., Sternberg, C. N., Morlock, R., Ramaswamy, K., Ivanescu, C., & Attard, G. (2019) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30898-2 · Cited by 107
What Are the Most Important Symptom Targets When Treating Advanced Cancer? A Survey of Providers in the National Comprehensive Cancer Network (NCCN)
Cella, D. F., Paul, D., Yount, S., Winn, R. J., Chang, C., Banik, D., & Weeks, J. C. (2003) · Cancer Investigation · doi:10.1081/cnv-120022366 · Cited by 107
Self-citation
The Chronology of Distress, Anxiety, and Depression in Older Prostate Cancer Patients
Nelson, C. J., Weinberger, M. I., Balk, E., Holland, J. C., BREITBART, W. S., & Roth, A. J. L. (2009) · The Oncologist · doi:10.1634/theoncologist.2009-0059 · Cited by 106
Mindfulness-Based Cognitive Therapy in Advanced Prostate Cancer: A Randomized Controlled Trial
Chambers, S. K., Occhipinti, S., Foley, E., Clutton, S., Legg, M., Berry, M., Stockler, M. R., Frydenberg, M., Gardiner, R. A., Lepore, S. J., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2016.68.8788 · Cited by 102
Effect of telehealth interventions on quality of life in cancer survivors: A systematic review and meta-analysis of randomized controlled trials
Li, J., Liu, Y., Jiang, J., Peng, X., & Hu, X. (2021) · International Journal of Nursing Studies · doi:10.1016/j.ijnurstu.2021.103970 · Cited by 98
Recommended Patient-Reported Core Set of Symptoms to Measure in Prostate Cancer Treatment Trials
Chen, R. C., Chang, P., Vetter, R. J., Lukka, H., Stokes, W. A., Sanda, M. G., Bruner, D. W., Reeve, B. B., & Sandler, H. M. (2014) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/dju132 · Cited by 97
Prospective Study of Outcomes after Percutaneous Biliary Drainage for Malignant Biliary Obstruction
Robson, P., Heffernan, N., Gönen, M., Thornton, R. H., Brody, L. A., Holmes, R., Brown, K. T., Covey, A. M., Fleischer, D., Getrajdman, G. I., et al. (2010) · Annals of Surgical Oncology · doi:10.1245/s10434-010-1045-9 · Cited by 97
Molecular markers as prognostic factors for local recurrence and radioresistance in head and neck squamous cell carcinoma
Smith, B. D., & Haffty, B. G. (1999) · Radiation Oncology Investigations · doi:10.1002/(sici)1520-6823(1999)7:3 · Cited by 81
PC‐SPES, a dietary supplement for the treatment of hormone‐refractory prostate cancer
Pfeifer, B. L., Pirani, J. F., Hamann, S. R., & Klippel, K. F. (2000) · British Journal of Urology · doi:10.1046/j.1464-410x.2000.00476.x · Cited by 93
Quality of Life During Treatment With Chemohormonal Therapy: Analysis of E3805 Chemohormonal Androgen Ablation Randomized Trial in Prostate Cancer
Morgans, A. K., Chen, Y., Sweeney, C. J., Jarrard, D. F., Plimack, E. R., Gartrell, B. A., Carducci, M. A., Hussain, M., Garcia, J. A., Cella, D. F., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2017.75.3335 · Cited by 92
Self-citation
Health outcomes of sexual and gender minorities after cancer: a systematic review
Pratt‐Chapman, M. L., Alpert, A. B., & Castillo, D. A. (2021) · Systematic Reviews · doi:10.1186/s13643-021-01707-4 · Cited by 93
Late Gastrointestinal Toxicity After Dose-Escalated Conformal Radiotherapy for Early Prostate Cancer: Results From the UK Medical Research Council RT01 Trial (ISRCTN47772397)
Syndikus, I., Morgan, R. C., Sydes, M. R., Graham, J. D., & Dearnaley, D. P. (2009) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2009.05.052 · Cited by 90
“Additionally, patients completed UCLA Prostate Cancer Index (UCLA-PCI) (12) and Functional Assessment of Cancer Therapy-Prostate (FACT-P) (13) scales to assess quality of life.”
MethodInfluential
Threat of Sexual Disqualification: The Consequences of Erectile Dysfunction and Other Sexual Changes for Gay and Bisexual Men With Prostate Cancer
Ussher, J. M., Perz, J., Rose, D., Dowsett, G. W., Chambers, S. K., Williams, S., Davis, I. D., & Latini, D. M. (2016) · Archives of Sexual Behavior · doi:10.1007/s10508-016-0728-0 · Cited by 89
Predictors of distress and quality of life in patients undergoing cancer therapy: impact of treatment type and decisional role
Hack, T. F., Pickles, T., Ruether, J. D., Weir, L. M., Bultz, B. D., Mackey, J. R., & Degner, L. F. (2009) · Psycho-Oncology · doi:10.1002/pon.1590 · Cited by 89
MRI-guided focused ultrasound focal therapy for patients with intermediate-risk prostate cancer: a phase 2b, multicentre study
Ehdaie, B., Tempany, C. M., Holland, F., Sjoberg, D. D., Kibel, A. S., Trinh, Q., Durack, J. C., Akın, O., Vickers, A. J., Scardino, P. T., et al. (2022) · The Lancet Oncology · doi:10.1016/s1470-2045(22)00251-0 · Cited by 88
Quality of Life and Pain in Advanced Stage Prostate Cancer: Results of a Southwest Oncology Group Randomized Trial Comparing Docetaxel and Estramustine to Mitoxantrone and Prednisone
Berry, D. L., Moinpour, C. M., Jiang, C. S., Ankerst, D. P., Petrylak, D. P., Vinson, L. V., Lara, P. N., Jones, S., Taplin, M. E., Burch, P. A., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.04.8207 · Cited by 88
Quality of life and sexuality of men with prostate cancer 3 years after cryosurgery
Robinson, J. W., Donnelly, B. J., Saliken, J. C., Weber, B., Ernst, S., & Rewcastle, J. C. (2002) · Urology · doi:10.1016/s0090-4295(02)01679-5 · Cited by 88
Effect of abiraterone acetate treatment on the quality of life of patients with metastatic castration-resistant prostate cancer after failure of docetaxel chemotherapy
Harland, S. J., Staffurth, J. N., Molina, A., Hao, Y., Gagnon, D. D., Sternberg, C. N., Cella, D. F., Fizazi, K. S., Logothetis, C. J., Kheoh, T. S., et al. (2013) · European Journal of Cancer · doi:10.1016/j.ejca.2013.07.144 · Cited by 87
“The FACT-P is a standard questionnaire that is validated in the mCRPC population [4,14–16].”
MethodSelf-citation
Mapping FACT-P and EORTC QLQ-C30 to Patient Health Status Measured by EQ-5D in Metastatic Hormone-Refractory Prostate Cancer Patients
Wu, E. Q., Mulani, P. M., Farrell, M. H., & Sleep, D. J. (2007) · Value in Health · doi:10.1111/j.1524-4733.2007.00195.x · Cited by 87
Leading the Way in Exercise and Diet (Project LEAD):
Demark‐Wahnefried, W., Morey, M. C., Clipp, E. C., Pieper, C. F., Snyder, D. C., Sloane, R. J., & Cohen, H. J. (2003) · Controlled Clinical Trials · doi:10.1016/s0197-2456(02)00266-0 · Cited by 86
“Quality of life—The Functional Assessment of Cancer Therapy breast and prostate quality of life (QOL) instruments are administered during each survey set; these instruments have been validated among women with early stage breast cancer and men with early stage prostate cancer [101,102].”
Method
Androgen deprivation therapy and estrogen deficiency induced adverse effects in the treatment of prostate cancer
Freedland, S. J., Eastham, J. A., & Shore, N. D. (2009) · Prostate Cancer and Prostatic Diseases · doi:10.1038/pcan.2009.35 · Cited by 83
Lack of Comprehension of Common Prostate Cancer Terms in an Underserved Population
Kilbridge, K. L., FRASER, G. J., Krahn, M. D., Nelson, E. M., Conaway, M. C., Bashore, R., Wolf, A. M. D., Barry, M. J., Gong, D. A., Nease, R. F., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.17.3468 · Cited by 81
Standardization of definitions in focal therapy of prostate cancer: report from a Delphi consensus project
Postema, A. W., de Reijke, T. M., Ukimura, O., van den Bos, W., Azzouzi, A.-R., Barret, É., Baumunk, D., Blana, A., Bossi, A., Brausi, M. A., et al. (2016) · World Journal of Urology · doi:10.1007/s00345-016-1782-x · Cited by 81
Symptomatic and quality‐of‐life outcomes after treatment for clinically localised prostate cancer: a systematic review
Whiting, P. F., Moore, T. H., Jameson, C., Davies, P. A., Rowlands, M., Burke, M., Beynon, R., Savović, J., & Donovan, J. (2016) · British Journal of Urology · doi:10.1111/bju.13499 · Cited by 81
Measuring health-related quality of life in men with prostate cancer: A systematic review of the most used questionnaires and their validity
Hamoen, E. H. J., de Rooij, M., Witjes, J. A., Barentsz, J. O., & Rovers, M. M. (2014) · Urologic Oncology Seminars and Original Investigations · doi:10.1016/j.urolonc.2013.10.005 · Cited by 86
“Table 2 provides an overview of the included questionnaires, their abbreviations, and the frequency of their use in studies [4–6,12–31].”
Background
High levels of medical mistrust are associated with low quality of life among black and white men with prostate cancer
Kinlock, B. L., Parker, L. J., Bowie, J. V., Howard, D. L., Laveist, T. A., & Thorpe, R. J. (2017) · Cancer Control · doi:10.1177/107327481702400112 · Cited by 81
The early toxicity of escalated versus standard dose conformal radiotherapy with neo-adjuvant androgen suppression for patients with localised prostate cancer: Results from the MRC RT01 trial (ISRCTN47772397)
Dearnaley, D. P., Sydes, M. R., Langley, R. E., Graham, J. D., Huddart, R. A., Syndikus, I., Matthews, J. H. L., Scrase, C. D., Jose, C. C., Logue, J. P., et al. (2007) · Radiotherapy and Oncology · doi:10.1016/j.radonc.2007.02.014 · Cited by 80
“Additionally, patients completed SF36 [18], UCLA prostate cancer index [19] and FACT-P [20] quality of life questionnaires.”
Method
Impact of enzalutamide on quality of life in men with metastatic castration-resistant prostate cancer after chemotherapy: additional analyses from the AFFIRM randomized clinical trial
Cella, D., Ivanescu, C., Holmstrom, S., Bui, C. N., Spalding, J., & Fizazi, K. (2015) · Annals of Oncology · doi:10.1093/annonc/mdu510 · Cited by 79
“FACT-G, Functional Assessment of Cancer Therapy-General; FACT-P, Functional Assessment of Cancer Therapy-Prostate; FAPSI, FACT Advanced Prostate Symptom Index; ITT, intention-to-treat; MMRM, mixed model repeated measures; PCS, prostate cancer subscale; PMM, pattern mixture model.”
InfluentialSelf-citation
Tolerability and efficacy of docetaxel in older men with metastatic castrate-resistant prostate cancer (mCRPC) in the TAX 327 trial
Horgan, A. M., Šeruga, B., Pond, G. R., Alibhai, S. M. H., Amir, E., de Wit, R., Eisenberger, M. A., & Tannock, I. F. (2014) · Journal of Geriatric Oncology · doi:10.1016/j.jgo.2013.12.001 · Cited by 79
A randomized, double-blind, multicenter, phase 2 study of a human monoclonal antibody to human αν integrins (intetumumab) in combination with docetaxel and prednisone for the first-line treatment of patients with metastatic castration-resistant prostate cancer
Heidenreich, A., Rawal, S. K., Szkarlat, K., Bogdanova, N. V., Dirix, L. Y., Stenzl, A., Welslau, M., Wang, G., Dawkins, F. W., de Boer, C. J., et al. (2012) · Annals of Oncology · doi:10.1093/annonc/mds505 · Cited by 79
Assessing longitudinal quality of life in prostate cancer patients and their spouses: a multilevel modeling approach
Song, L., Northouse, L., Braun, T., Zhang, L., Cimprich, B., Ronis, D. L., & Mood, D. (2010) · Quality of Life Research · doi:10.1007/s11136-010-9753-y · Cited by 78
“It measures general QOL in physical, social/family, emotional, and functional domains [ 46 ].”

Authors: Esper, P., Mo, F., Chodak, G., Sinner, M., Cella, D., & Pienta, K. J.
Affiliations: Rush University Medical Center (US)
Corresponding author: Esper, Peg
ORCID: Cella, David
Pienta, Kenneth J.
Venue: Urology
Publisher: Elsevier BV
Published: 1997-12
Volume: 50
Issue: 6
Pages: 920-928
ISSN: 0090-4295 (ISSN-L)
DOI: 10.1016/s0090-4295(97)00459-7
OpenAlex: W2004909463
Cited by: 696
References: 22
Citations by year: 2026: 18 · 2025: 22 · 2024: 34 · 2023: 25 · 2022: 45 · 2021: 34 · 2020: 20 · 2019: 31 · 2018: 35 · 2017: 29 · 2016: 33 · 2015: 30 · 2014: 28 · 2013: 31 · 2012: 27
FWCI: 4.00
Type: journal article
Language: en
Open access: closed
Licence: www.elsevier.com/tdm/userlicense/1.0/ (tdm)
Locations: Urology (publishedVersion)
PubMed (publishedVersion)
Topics: Health Sciences › Medicine › Oncology › Cancer survivorship and care
Health Sciences › Medicine › Oncology › Cancer-related cognitive impairment studies
Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Health Systems, Economic Evaluations, Quality of Life
Keywords: prostate cancer, quality of life, Functional Assessment of Cancer Therapy, questionnaire development, concurrent validity, internal consistency, sensitivity to change, prostate-specific antigen, performance status, disease stage
MeSH terms: Aged, Aged, 80 and over, Chicago, Humans, Male, Michigan, Middle Aged, Prostatic Neoplasms, Quality of Life, Surveys and Questionnaires, Sensitivity and Specificity, Reproducibility of Results

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Measuring quality of life in men with prostate cancer using the Functional Assessment of Cancer Therapy-prostate instrument

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Citations

Cites

Cited by

Related

Metadata

Record

About these checks